Atlas Trials

A Study to Learn About Patients With Non-Small Cell Lung Cancer (NSCLC) Who Took Lorlatinib as Their First Treatment

Clinical trial NCT07567352 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT07567352
Sponsor
Pfizer
Status
ACTIVE_NOT_RECRUITING
Study type
OBSERVATIONAL
Non-Small-Cell LungALK-positive Advanced NSCLCALK-positive Non-small-cell Lung CancerALK-positive NSCLC
Start date
2026-05-01
Primary completion
2026-07-31
Enrollment
200

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.